Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Mattia Ferro

2 papers in the library · 16 citations · publishing 2022-2024

Papers

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

Brain Sciences August 18, 2024 Gianmarco Salvetti, Daniele Saccenti, Andrea Stefano Moro et al. 16 citations

Psilocybin, a psychedelic compound, shows high effectiveness in reducing depressive symptoms in people with major depressive disorder (MDD) or treatment-resistant depression (TRD). A systematic review and meta-analysis of 12 studies found that both single-dose and two-dose psilocybin treatments significantly lowered depression severity. Two-dose administration sometimes produced more pronounced and lasting effects, but it remains unclear whether this is due to dosage or other factors. The findings suggest psilocybin is a promising emerging treatment for these conditions, though standardized trials comparing dosing strategies are needed.

DOI: 10.3390/brainsci14080829 (opens in new tab) Mdd Major depressive disorder Treatment-resistant depression Mental health treatment +6

Occlusion of dopamine-dependent synaptic plasticity in the prefrontal cortex mediates the expression of depressive-like behavior and is modulated by ketamine

Scientific Reports June 30, 2022 J. Lamanna, Francesco Isotti, Mattia Ferro et al.

In rats, vulnerability to chronic mild stress (CMS) is linked to a loss of dopamine-dependent synaptic plasticity in the medial prefrontal cortex (mPFC), likely due to altered AMPA receptor expression. This deficit is not present when rats receive a sub-anesthetic dose of ketamine, which may recruit dopaminergic areas like the ventral tegmental area. Chronic stress also shifts synaptic drive from the infralimbic and prelimbic subregions of the mPFC toward the basolateral amygdala, an effect that ketamine counteracts. These findings clarify neurophysiological mechanisms underlying stress vulnerability and ketamine's antidepressant action.

DOI: 10.1038/s41598-022-14694-w (opens in new tab) Full text (opens in new tab) Medicine Psychology